0.07 USD
▼-0.03-37.11%
盘后 0.13 -2.99%
2026-09-01
市值
$2.31M
市盈率
—
EPS
-3.15
股息率
—
52 周区间
0.12 – 4.29
成交量
47.48M
Beta
0.29
目标价
18.33
52W 低 0.1252W 高 4.29
价格走势
公司简介
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmede...
关联新闻
- Biopharma firm BioXcel Therapeutics files for bankruptcy in US
AI-driven biopharma firm BioXcel Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. on Thursday.